Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

587
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
587
Relative Risk01:12

Relative Risk

2.6K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.6K
Hazard Ratio01:12

Hazard Ratio

742
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
742
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

582
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
582
Actuarial Approach01:20

Actuarial Approach

385
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
385
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

728
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
728

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hybrid zeolitic imidazolate frameworks with catalytically active TO4 building blocks.

Angewandte Chemie (International ed. in English)·2010
Same author

Whiter matter abnormalities in medication-naive subjects with a single short-duration episode of major depressive disorder.

Psychiatry research·2010
Same author

A new comorbidity index: the health-related quality of life comorbidity index.

Journal of clinical epidemiology·2010
Same author

S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer.

International journal of biological sciences·2010
Same author

Nano-sized SnSbAgx alloy anodes prepared by reductive co-precipitation method used as lithium-ion battery materials.

Journal of nanoscience and nanotechnology·2010
Same author

Complementary diffusion tensor imaging study of the corpus callosum in patients with first-episode and chronic schizophrenia.

Journal of psychiatry & neuroscience : JPN·2010

Related Experiment Video

Updated: Apr 20, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K

Towards actionable risk stratification: a bilinear approach.

Xiang Wang1, Fei Wang1, Jianying Hu1

  • 1IBM T.J. Watson Research Center, Yorktown Heights, NY, USA.

Journal of Biomedical Informatics
|December 3, 2014
PubMed
Summary

This study introduces a new bilinear model for risk stratification, improving clinical decision support. The model accurately predicts individual patient risk and provides actionable cohort insights for conditions like Congestive Heart Failure (CHF).

Keywords:
Bilinear modelDimensionality reductionLogistic regressionMatrix factorizationRisk stratification

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

798
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K

Related Experiment Videos

Last Updated: Apr 20, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

798
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K

Area of Science:

  • Clinical Informatics
  • Biostatistics
  • Machine Learning in Healthcare

Background:

  • Current risk stratification methods primarily focus on individual patient scores, lacking cohort-level clinical context.
  • Existing approaches reduce patients to scores, diminishing their clinical context and hindering actionable insights.
  • Effective clinical decision support requires comprehensive risk assessment that includes both individual risk and cohort-level context.

Purpose of the Study:

  • To propose a novel bilinear model for risk stratification that addresses limitations of existing methods.
  • To develop a model that simultaneously predicts individual risk, stratifies cohorts by risk and characteristics, and embeds patients in interpretable clinical contexts.
  • To enhance clinical decision support systems with more comprehensive and actionable risk stratification.

Main Methods:

  • Development of a bilinear model for risk stratification.
  • Application of the model to a cohort of 4977 patients, including 1127 diagnosed with Congestive Heart Failure (CHF).
  • Evaluation of the model's ability to predict individual risk and stratify patient cohorts based on risk and clinical characteristics.

Main Results:

  • The proposed bilinear model accurately predicts the onset risk of Congestive Heart Failure (CHF).
  • The model successfully stratifies patient cohorts, considering both risk scores and clinical characteristics.
  • The model provides rich, interpretable, and actionable clinical insights into the patient cohort.

Conclusions:

  • The developed bilinear model offers a significant advancement in risk stratification for clinical decision support.
  • This approach overcomes the limitations of score-based segmentation by providing contextualized patient information.
  • The model demonstrates potential for improving patient care by offering accurate predictions and actionable clinical insights for conditions like CHF.